Sapphiros invests in growth-stage diagnostic companies, focusing on technologies that prioritize innovation and patient-centric approaches. The company possesses a portfolio of capabilities and technologies encompassing innovative sample collection, next-generation diagnostics, computational biology, and printed electronics. These elements contribute to the global accessibility of crucial diagnostic results for consumers.
Biocrucible is developing next-generation diagnostics based upon breakthrough advances in biomolecular condensate formation.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.